Antitumor agent-114 (compound 14c) (2, 0.67, 0.22 mg/kg for intratumoral on day 1, 4, and 7) modulates tumor eradication by systemic immune activation in 4T1 tumor-bearing mice model[1].
| Animal Model: | 4T1 tumor-bearing mice model[1] |
| Dosage: | 2, 0.67, 0.22 mg/kg |
| Administration: | Intratumoral (i.t.) |
| Result: | Reached 80 and 70% tumor growth inhibition (TGI) in the groups treated with 2 and 0.67 mg/kg.
Induced tumor regression in 7 of 8 mice at a dose of 2 mg/kg.
|
